Actionable Results

 

Cxbladder is a Genomic Urine Test for Bladder Cancer

Cxbladder is a cutting-edge genomic urine test that quickly and accurately detects or rules out bladder cancer. The test works at a molecular level, measuring five biomarker genes to detect the presence or absence of bladder cancer.

Reliable: More reliable and objective than many other urine-based tests, Cxbladder utilizes high sensitivity and Negative Predictive Value to provide accurate results.

Actionable: Cxbladder provides actionable results to facilitate the early detection of bladder cancer by either helping to rule out the disease or to complement other diagnostic procedures and tests.

Efficient: Non-invasive and pain free, Cxbladder provides a complete sampling system for collection of the patient’s urine sample and shipment to our laboratory. In response to the recent outbreak of COVID-19, we are now offering an in-home sampling service to US patients.

Credible: Over ten years of research has identified five specific messenger RNA (mRNA) biomarkers that represent a bladder cancer signature. Cxbladder has been validated in large multicenter clinical studies published in highly respected peer-reviewed journals, while the clinical utility of the test has been reinforced in real-world case studies spanning multiple sites.
Browse Our Library of Clinical Publications 

A Suite of Tests Optimized to Primary Detection and Surveillance

Cxbladder comes as a suite of three products each optimized for a specific point along the patient journey.

Cxbladder Triage

Designed for patients presenting with hematuria. Cxbladder Triage analyzes the presence of five biomarker genes alongside information on known bladder cancer risk factors like age, gender and smoking history to rule out patients with a low risk of having the disease.

Cxbladder Triage provides accurate results and reassurance that can reduce the need for further invasive procedures.

Cxbladder Detect

In cases where a patient is symptomatic and bladder cancer looks likely, Cxbladder Detect can help confirm your diagnosis.

By detecting and quantifying signs of cancer at the molecular level, Cxbladder Detect outperforms other urine-based tests, making it an ideal choice for bladder cancer testing when patients present with significant symptoms. Cxbladder Detect can also be used as an adjunct to cystoscopy or as a substitute for other X-ray tests to improve overall detection accuracy.

Cxbladder Monitor

Developed specifically for patients undergoing surveillance for recurrent bladder cancer. The test combines clinical information linked to previous bladder cancer with measured biomarker genes to help rule out the presence of a recurrent tumour, or to indicate that further clinical investigation is required.

Cxbladder Monitor can provide accurate results with a single urine sample, and test is often used as a non-invasive monitoring alternative to reduce the need for frequent cystoscopies.
Request More Info on Triage, Detect or Monitor

Cxbladder In-Home Sampling is Now Available

Cxbladder’s unique urine sampling system is non-invasive and easy-to-use. The process is quick and painless, taking only minutes.

To simplify and streamline the bladder cancer testing process, we are now offering the Cxbladder In-Home Sampling Program for surveillance patients and those presenting with hematuria across the US. Participating patients have the option of submitting their urine sample in the comfort of their own home without the need to physically visit their Urologist.
Learn More

The Difference in Cancer Detection

Cxbladder is a reliable test for bladder cancer that can help you make informed treatment and care decisions.

Most symptomatic or surveillance patients do not have bladder cancer. Cxbladder enables the accurate rule out of patients with hematuria and those being monitored for recurrence, reducing the burden of cystoscopy and sparing patients anxiety and discomfort. The test also solves a diagnostic dilemma, accurately resolving atypical cytology and inconclusive cystoscopy in the evaluation of patients presenting with hematuria or being monitored for recurrence.
Contact Us to Request More Information

 

Last Updated: 18 Jun 2020 09:10 am

• References

  Cxbladder was developed by a company whose passion and focus is cancer diagnostics and prognostics to improve patient outcomes. See our full list of clinical publications.

  Pacific Edge is responsible for the development and determination of the performance characteristics for Cxbladder. Because Cxbladder is a Laboratory Developed Test (LDT), Cxbladder has not been cleared or approved by the US Food and Drug Administration (FDA).